Case-control study: sleep disorders linked to more severe outcomes from COVID-19, study suggests.
News Release: Sleep disorders linked with more severe outcomes from COVID-19, study suggests – Cleveland Clinic Original Study: Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System – JAMA Network Open Commentary: Some sleep disorders may lead to worse COVID-19 outcomes – CIDRAP Commentary on Twitter […]
The post Case-control study: sleep disorders linked to more severe outcomes from COVID-19, study suggests. appeared first on Links Medicus.
Observational study found monitoring outpatients with Covid-19 using text messages that allowed the report of worsening symptoms was associated with improved outcomes.
Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home – Annals of Internal Medicine News Release: Automated Texting System Saved Lives Weekly During First COVID Surge – Penn Medicine Commentaries: Monitoring outpatients by text appeared to reduce mortality from COVID-19 – ACP Internist Texting saved lives during Covid. What does that […]
The post Observational study found monitoring outpatients with Covid-19 using text messages that allowed the report of worsening symptoms was associated with improved outcomes. appeared first on Links Medicus.
M-A: Prediction of extubation outcome in critically ill patients.
Prediction of extubation outcome in critically ill patients: a systematic review and meta-analysis – Critical Care
The post M-A: Prediction of extubation outcome in critically ill patients. appeared first on Links Medicus.
Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used.
Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation Related: COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”. [Press release – not […]
The post Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used. appeared first on Links Medicus.
Pfizer’s pill is the latest COVID treatment to show promise. Here are some more.
Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation Related: COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”. [Press release – not published yet] […]
The post Pfizer’s pill is the latest COVID treatment to show promise. Here are some more. appeared first on Links Medicus.
Review: Vaccine-induced immune thrombotic thrombocytopenia.
Vaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology Related: Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. […]
The post Review: Vaccine-induced immune thrombotic thrombocytopenia. appeared first on Links Medicus.
RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome.
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine Commentary on Twitter NEW Research—In pts w/ #COVID19 who received IMV for mod-to-sev #ARDS, intravenous immunoglobulins did not improve clinical outcomes at day 28 Phase 3 ICAR trial from Prof Tarek […]
The post RCT: Intravenous immunoglobulins do not improve outcomes in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome. appeared first on Links Medicus.
IDSA/ASM Consensus Review Document: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping.
Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document – Clinical Infectious Diseases News Release: New review article outlines potential of SARS-CoV-2 genetic sequencing in patient care – American Society for Microbiology
The post IDSA/ASM Consensus Review Document: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping. appeared first on Links Medicus.
[Preprint] Risk of severe COVID-19 is rare among fully vaccinated individuals in England.
Commentary: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical Original Study: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv
The post [Preprint] Risk of severe COVID-19 is rare among fully vaccinated individuals in England. appeared first on Links Medicus.
Populational study in Qatar showed the effectiveness against SARS-CoV-2 Delta-induced severe, critical or fatal disease was 93.4% for the Pfizer vaccine and 96.1% for Moderna.
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine Commentary on Twitter A study in @NatureMedicine shows that mRNA COVID-19 vaccines are highly effective at preventing severe outcomes and death caused by the SARS-CoV-2 Delta variant in Qatar despite substantially lower effectiveness at blocking infection. https://t.co/V09Ma583fy pic.twitter.com/QG2HaDsrCo […]
The post Populational study in Qatar showed the effectiveness against SARS-CoV-2 Delta-induced severe, critical or fatal disease was 93.4% for the Pfizer vaccine and 96.1% for Moderna. appeared first on Links Medicus.